Insider Stock Trading History of Babu Yarlagadda S


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Babu Yarlagadda S since year 2005. The trader's CIK number is 1452635. At the time of this reporting, Babu Yarlagadda S is the Senior VP - Drug Discovery of Biocryst Pharmaceuticals Inc . (stock ticker symbol BCRX). See this page for all insider trading activities at Biocryst Pharmaceuticals Inc .


Stock purchases, sales, and option exercises reported by insider Babu Yarlagadda S since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2016-08-25 BCRX Biocryst Pharmaceuticals Inc Sale 30,000 4.06 121,799
2015-03-19 BCRX Biocryst Pharmaceuticals Inc Sale 12,105 10.16 122,986
2015-03-05 BCRX Biocryst Pharmaceuticals Inc Sale 37,400 10.59 396,066
2015-03-04 BCRX Biocryst Pharmaceuticals Inc Sale 10,495 10.50 110,197
2014-03-04 BCRX Biocryst Pharmaceuticals Inc Option Ex 28,816 7.32 210,933
2014-03-04 BCRX Biocryst Pharmaceuticals Inc Sale 40,642 12.57 510,869
2014-02-24 BCRX Biocryst Pharmaceuticals Inc Option Ex 23,179 4.30 99,669
2012-03-02 BCRX Biocryst Pharmaceuticals Inc Sale 837 4.78 4,000
2012-02-29 BCRX Biocryst Pharmaceuticals Inc Option Ex 53,668 .00 0
2012-02-22 BCRX Biocryst Pharmaceuticals Inc Option Ex 30,912 1.14 35,239
2012-02-22 BCRX Biocryst Pharmaceuticals Inc Sale 30,912 4.22 130,448
2009-10-26 BCRX Biocryst Pharmaceuticals Inc Sale 6,400 10.85 69,420
2009-10-21 BCRX Biocryst Pharmaceuticals Inc Sale 200 10.00 2,000
2009-10-20 BCRX Biocryst Pharmaceuticals Inc Sale 3,400 10.00 34,000
2009-09-23 BCRX Biocryst Pharmaceuticals Inc Sale 20,000 9.14 182,719

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Babu Yarlagadda S (Senior VP - Drug Discovery of Biocryst Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.